Related Experiment Video
Updated: Jan 15, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Successful Management of Refractory Pulmonary Mucormycosis Using Intracavitary Amphotericin B: A Case Report and
Yujie Gao1,2, Hansheng Wang1,2, Xiao Feng Bai2
1Department of Pulmonary and Critical Care Medicine, Shiyan Key Laboratory of Major Chronic Respiratory Disease, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Abstract:
BACKGROUND Mucormycosis is a rapidly invasive, highly fatal infection typically affecting immunocompromised patients, such as those with diabetes, hematologic malignancies, or HIV. We report a case of pulmonary mucormycosis in a female patient in which initial systemic therapy failed. CT-guided intracavitary amphotericin B instillation was used as salvage therapy. This approach delivered high-dose antifungal medication directly to the infection site, leading to significant clinical and radiological improvement. CASE REPORT We report a case of pulmonary mucormycosis complicated with Klebsiella pneumoniae infection in a 51-year-old female patient who had a history of diabetes. This patient was admitted to the hospital for dyspnea, chest pain, and fever, and a chest CT on admission suggested multiple inflammatory lesions in both lungs (involving abscesses or fungi). Bronchoscopy revealed left upper-lobe suppurative inflammation. Initial bronchoalveolar lavage fluid (BALF) tests (smears, culture, GM, X-pert) were negative. Finally, the BALF was tested by targeted next-generation sequencing (tNGS), and the diagnosis of pulmonary mucormycosis co-infected with Klebsiella pneumoniae was confirmed. After 21 days of treatment with intravenous amphotericin B and posaconazole, lung nodules/cavities (Mucor) showed no improvement, suggesting inadequate local drug penetration. The patient was ultimately treated with combined local (CT-guided intrapulmonary amphotericin B injection and nebulization) and systemic (intravenous amphotericin B and posaconazole) antifungal therapy, resulting in partial resolution of pulmonary cavities on follow-up CT. CONCLUSIONS This case report presents an innovative management strategy for mucormycosis; combined local and systemic antifungal therapy achieved clinical improvement despite limited intracavitary injections, providing a potential therapeutic approach for this challenging infection.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Cystic Fibrosis: Management
Sinus disease and chronic...

